Publicaciones científicas

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, M.B., Ch.B., S. Vincent Rajkumar, M.D., Meletios A. Dimopoulos, M.D., Tamás Masszi, M.D., Ph.D., Ivan Špička, M.D., Ph.D., Albert Oriol, M.D., Roman Hájek, M.D., Ph.D., Laura Rosiñol, M.D., Ph.D., David S. Siegel, M.D., Ph.D., Georgi G. Mihaylov, M.D., Ph.D., Vesselina Goranova-Marinova, M.D., Ph.D., Péter Rajnics, M.D., Ph.D., Aleksandr Suvorov, M.D., Ruben Niesvizky, M.D., Andrzej J. Jakubowiak, M.D., Ph.D., Jesus F. San-Miguel, M.D., Ph.D., Heinz Ludwig, M.D., Michael Wang, M.D., Vladimír Maisnar, M.D., Ph.D., Jiri Minarik, M.D., Ph.D., William I. Bensinger, M.D., Maria-Victoria Mateos, M.D., Ph.D., Dina Ben-Yehuda, M.D., Vishal Kukreti, M.D., Naseem Zojwalla, M.D., Margaret E. Tonda, Pharm.D., Xinqun Yang, Ph.D., Biao Xing, Ph.D., Philippe Moreau, M.D., and Antonio Palumbo, M.D. for the ASPIRE Investigators 

Revista: The New England Journal of Medicine

Fecha: 06-dic-2014

Hematología y Hemoterapia

BACKGROUND
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma.

METHODS
We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival.

RESULTS
Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001).

The median overall survival was not reached in either group at the interim analysis. The Kaplan–Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04).

The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life.

CONCLUSIONS
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk–benefit profile.

CITA DEL ARTÍCULO  N Engl J Med. 2015 Jan 8;372(2):142-152. Epub 2014 Dec 6.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra